Summary & Overview
CPT 86596: VGCC Antibody Assay for Lambert–Eaton Myasthenic Syndrome
CPT code 86596 identifies a diagnostic laboratory assay for antibodies to voltage‑gated calcium channels (VGCC), most commonly performed by radioimmunoassay. The presence of VGCC antibodies, particularly P/Q‑type and sometimes N‑type, is clinically significant for diagnosing Lambert–Eaton myasthenic syndrome (LEMS), an autoimmune cause of muscle weakness that is often paraneoplastic with small cell lung cancer. Nationwide, accurate coding for this specialized serologic test supports appropriate diagnostic workflows, lab billing, and surveillance of autoimmune neuromuscular disorders.
Key payers covered in this publication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for CPT code 86596, typical sites and service type, and an overview of what to expect in payer coverage and billing practice. The report highlights benchmark considerations, common clinical indications tied to LEMS and SCLC, and policy or billing items relevant to laboratory and neurology stakeholders. Content is framed for a national audience and intended to support coding accuracy, clinical interpretation, and administrative clarity for facilities and clinicians handling VGCC antibody testing.
Billing Code Overview
CPT code 86596 describes a laboratory test to detect antibodies to voltage‑gated calcium channels (VGCC) in a patient specimen, commonly serum. The assay is most often performed using radioimmunoassay (RIA) techniques and identifies antibodies (notably P/Q‑type and sometimes N‑type) that support the diagnosis of Lambert–Eaton myasthenic syndrome (LEMS), an autoimmune neuromuscular disorder frequently associated with small cell lung cancer (SCLC).
Service type: Diagnostic serologic test
Typical site of service: Clinical laboratory or hospital laboratory (ambulatory or inpatient specimen processing)
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old current or former smoker presents with progressive proximal muscle weakness, dry mouth, and autonomic symptoms. The neurologist suspects Lambert–Eaton myasthenic syndrome (LEMS) after electrodiagnostic testing reveals reduced compound muscle action potential amplitude that increases after high-frequency stimulation or after exercise. The clinician orders serum testing for antibodies to voltage-gated calcium channels (VGCC), typically P/Q-type and sometimes N-type, to support the autoimmune diagnosis and to screen for an underlying malignancy such as small cell lung cancer (SCLC). The sample is collected in an outpatient phlebotomy clinic or hospital laboratory and sent to a reference immunology lab for radioimmunoassay (RIA) or equivalent serologic testing. Results are returned to the ordering neurologist who integrates the antibody result with clinical exam, electrodiagnostic studies, and oncologic evaluation to guide additional testing (e.g., chest imaging) or management. Typical site of service: outpatient laboratory, hospital outpatient clinic, or reference laboratory. Service type: immunology/serology diagnostic testing for autoantibodies.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician interpretation component separately from the technical lab component when allowed. |